Development and validation of a TRUS-based prostate cancer prediction model with PSAD stratification in a two-center Western Chinese cohort: a retrospective cohort study with cost-effectiveness analysis
Asian Journal of Andrology · 17.11.2026
DOI: 10.4103/aja202656 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Asian Journal of Andrology, online erschienen am 17.11.2026. Verfasst von Yu Liang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ultrasound Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China…. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
Prostate-specific antigen screening has a low positive predictive value in low-incidence populations, leading to unnecessary biopsies. In this study, we developed and validated a prostate cancer prediction model incorporating transrectal ultrasound features and prostate-specific antigen density stratification and evaluated its cost-effectiveness. This dual-center retrospective study included 767 men with prostate-specific antigen levels of ≥4 ng ml −1 (training cohort, n = 558; validation cohort, n = 209). Prostate-specific antigen density was stratified into five categories. A logistic regression model was developed and validated. The cost-effectiveness of four screening strategies was evaluated. Five independent predictors were identified: age, prostate-specific antigen density stratification, extraprostatic extension, solid hypoechoic lesions, and unclear boundary. The model showed good discrimination (0.915 and 0.943 in the training and validation cohorts, respectively) and calibration (Hosmer–Lemeshow P = 0.57). The high-threshold strategy (≥0.5) avoided 47.0% of biopsies, and had the lowest total cost. In the biopsy cohort, the cost per cancer detected was the lowest in men with prostate-specific antigen density ≥0.15 ng ml −2 (83 295 Chinese Yuan). This model can reduce unnecessary biopsies in men with elevated prostate-specific antigen levels identified from opportunistic testing, but it is not suitable for population-wide screening given its unfavorable cost-effectiveness. It provides incremental value in resource-limited settings rather than serves as a practice-changing alternative to contemporary magnetic resonance imaging (MRI)-based pathways.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ultrasound Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.
- Department of Ultrasound Imaging, Chongqing Yunyang County People's Hospital, Chongqing 404500, China.
Zitieren
APA
Liang, Y., Yang, Y. M., Zhang, J., Zhang, Y. Q., Li, X., Lyu, M. H., Li, Y. Q., Ai, X., Li, F., & Luo, J. (2026). Development and validation of a TRUS-based prostate cancer prediction model with PSAD stratification in a two-center Western Chinese cohort: a retrospective cohort study with cost-effectiveness analysis. Asian Journal of Andrology. https://doi.org/10.4103/aja202656
Vancouver
Liang Y, Yang YM, Zhang J, Zhang YQ, Li X, Lyu MH, et al. Development and validation of a TRUS-based prostate cancer prediction model with PSAD stratification in a two-center Western Chinese cohort: a retrospective cohort study with cost-effectiveness analysis. Asian Journal of Andrology. 2026. doi:10.4103/aja202656
BibTeX
@article{Liang2026,
author = {Liang, Yu and Yang, Yu-Min and Zhang, Jing and Zhang, Yi-Qiong and Li, Xue and Lyu, Mao-Hua and Li, Yuan-Qiang and Ai, Xin and Li, Fei and Luo, Jun},
title = {Development and validation of a TRUS-based prostate cancer prediction model with PSAD stratification in a two-center Western Chinese cohort: a retrospective cohort study with cost-effectiveness analysis},
journal = {Asian Journal of Andrology},
year = {2026},
doi = {10.4103/aja202656}
}
EUVIMED